ADVA launches TeraFlex ™ CoreChannel ™ for industry’s longest 800G reach
ADVA (FSE: ADV) today launched its FSP 3000 TeraFlex™ CoreChannel™, giving internet content providers (ICPs) and communication service providers (CSPs) the power to transmit 800Gbit/s over greater distances than ever before. Using 140GBd sub-carrier technology, the new CoreChannel™ sled offers the market’s longest reach for a single-channel 800Gbit/s solution, enabling ultra-high-capacity transport over existing and new network infrastructure of more than 1,600km. This provides an improvement in reach of over 50% compared with 95GBd technologies. As well as the longest reach, the sled offers the highest client port flexibility. TeraFlex™ CoreChannel™ can support 400GbE, 100GbE and 10GbE or a mixture of client speeds. The solution is now being trialed by major carriers and R&E network operators.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210608005217/en/
ADVA’s CoreChannel™ transmits 800G data channels 50% farther than any competing solution (Photo: Business Wire)
“Network operators across the planet have been harnessing our FSP 3000 TeraFlex™ to unlock the full potential of their fiber assets. Our compact, plug-and-play terminal offers a simple and cost-efficient way to maximize the capacity of optical infrastructure. Today we’re making it even more powerful with the introduction of our CoreChannel™ sled. Customers can now transport data at 400Gbit/s and 800Gbit/s over longer distances than ever before with a solution that delivers the lowest possible cost per bit per kilometer,” said Christoph Glingener, CTO, ADVA. “Our FSP 3000 TeraFlex™ CoreChannel™ technology offers an enormous boost to operators transmitting services across countries and continents. What’s more, long-haul transport with TeraFlex™ CoreChannel™ is even more efficient and reliable thanks to its superior link signal-to-noise (SNR) requirements and higher network performance.”
The launch of ADVA’s CoreChannel™ sled positions the FSP 3000 TeraFlex™ as the industry’s most efficient high-capacity platform for all applications from metro to core to ultra-long-haul submarine links. Compatible with deployed infrastructure, the new solution can transmit 800Gbit/s over more than 1,600km. What’s more, TeraFlex™ CoreChannel™ delivers industry-leading SNR requirements making it resilient to transmission impairments. Along with the bandwidth flexibility and fractional QAM capabilities of the TeraFlex™ terminal, this ensures 800Gbit/s transport with highest efficiency, highest performance and lowest cost. Featuring multi-rate client support, the CoreChannel™ sled can transport any mix of 400GbE, 100GbE and 10GbE services, providing customers with flexibility and protecting their investment as they migrate to higher speeds.
“The launch of our FSP 3000 TeraFlex™ CoreChannel™ changes the game for terrestrial long-haul and regional transport. It gives ICPs and CSPs the ability to inject new capacity into their deployed networks. Now they can drive line speeds of up to 800Gbit/s over distances 50% longer than can be achieved with 95GBd solutions. That advantage will be key to tackling ever-increasing data growth without adding significant cost and complexity,” commented Cornelius Fürst, director, product line management, ADVA. “With its unrivaled reach, multi-rate client flexibility and rich performance settings, TeraFlex™ CoreChannel™ redefines the economics of backbone networks. It will play a key role in accelerating the delivery of high-bandwidth, feature-rich services over ultra-long-haul global infrastructure. And because it can be flexibly configured for lower data rates, it supports a smooth transition to high-speed connectivity.”
Watch this video for more information on the FSP 3000 TeraFlex™ CoreChannel™: https://adva.li/fsp-3000-teraflex-corechannel-product-video.
Further details are also available in this Tech Cam video: https://adva.li/fsp-3000-teraflex-corechannel-tech-cam.
Supporting slides can be viewed here: https://adva.li/fsp-3000-teraflex-corechannel-slides.
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.
ADVA Optical Networking SE, Munich, Germany
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
t +44 1904 699 358
t +49 89 890 665 854
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Celltrion Healthcare presents the first real-world data for Truxima ® (biosimilar rituximab) in patients with diffuse large B-cell lymphoma at the EHA 2021 Virtual Congress12.6.2021 17:45:00 CEST | Press release
Celltrion Healthcare today presented new data from its post-approval study evaluating the real-world clinical effectiveness and safety of Truxima® (biosimilar rituximab, CT-P10) in patients with diffuse large B-cell lymphoma (DLBCL) at the European Hematology Association (EHA) 2021 Virtual Congress.1 CT-P10 was granted European Medicines Agency approval in 2017 for the treatment of rheumatoid arthritis (RA) and specific blood cancers, including non-Hodgkin’s lymphoma (NHL).2 DLBCL is the most common subtype of NHL, representing an estimated 30-40% of adult cases.3,4,5,6 This non-interventional post-authorisation safety study (PASS) involved the collection of patient-level data from hospital medical records for patients with DLBCL who received CT-P10 treatment in five European countries (United Kingdom, Spain, France, Germany and Italy). CT-P10 treatment pattern data were collected retrospectively during the 30-month observation period and patients were selected based on the treatment t
Janssen Announces Results from Phase 3 MAIA Study Showing Significant Overall Survival Benefits for Treatment with DARZALEX ® ▼ (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma Who are Transplant Ineligible12.6.2021 09:01:00 CEST | Press release
The Janssen Pharmaceutical Companies of Johnson & Johnson announced overall survival (OS) results from the Phase 3 MAIA (NCT02252172) study showing the addition of DARZALEX® ▼(daratumumab) to lenalidomide and dexamethasone (D-Rd) resulted in a statistically significant survival benefit over lenalidomide and dexamethasone (Rd) alone in patients with newly diagnosed multiple myeloma (NDMM) who were ineligible for autologous stem cell transplant (ASCT) and were treated to progression.1 These data were featured in the European Hematology Association (EHA) 2021 Virtual Press Briefing and will be presented as a late-breaking abstract during the EHA Virtual Congress (Abstract #LB1901). The prespecified interim analysis for OS found that after a median follow-up of nearly five years (56.2 months), a 32 percent reduction in the risk of death was observed in the D-Rd treatment arm vs. Rd arm.1 Median OS was not reached in either arm [hazard ratio (HR): 0.68, 95 percent confidence interval (CI),
New Phase 3 Study Results Show IMBRUVICA ® (ibrutinib)-Based Combination Regimen as an All-Oral Fixed-Duration Treatment Demonstrated Superior Progression-Free Survival in Adult Patients with Previously Untreated Chronic Lymphocytic Leukaemia12.6.2021 09:00:00 CEST | Press release
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced primary results from the pivotal Phase 3 GLOW study (NCT03462719) evaluating fixed-duration IMBRUVICA® (ibrutinib) plus venetoclax (I+V) compared to chlorambucil plus obinutuzumab (Clb+O) for first-line treatment of elderly or unfit patients with chronic lymphocytic leukaemia (CLL). The study demonstrated superior progression-free survival (PFS) of a once-daily, all-oral, fixed-duration regimen of I+V versus Clb+O as first-line treatment of CLL; the study also showed improved duration of remission and significantly improved depth of remission.1 With I+V, undetectable minimal residual disease (uMRD) in peripheral blood (PB) was sustained by 85 percent of patients one year after end of treatment.1 The safety and tolerability profile of I+V was consistent with CLL treatment in an older population with comorbidities.1 These data were featured in the European Hematology Association (EHA) 2021 Virtual Press Briefing an
Alluzience ® , the first ready-to-use BoNT-A neuromodulator, receives positive decision for use in Europe11.6.2021 11:53:00 CEST | Press release
Galderma today announced that Alluzience® has completed its European decentralized procedure resulting in a positive decision for the first ready-to-use neuromodulator, a wrinkle relaxing injection, in Europe. National approvals will now take place across the region in line with local processes in each country. Designed for precision, Alluzience® is a liquid form of botulinum toxin type A intended for use in adult patients as a treatment to temporarily improve the appearance of moderate to severe glabellar lines (vertical lines between the eyebrows), when the severity of these lines has an important psychological impact on the patient.1 "The introduction of Alluzience® marks a new era in treatment innovation for upper facial lines in Europe. Like many aspects of physical appearance, glabellar lines can have a significant impact on patients’ confidence and wellbeing. I’ve heard first-hand that the transition to living and working in a virtual world has only exacerbated these issues. As
Secure Communities Forum: Behavioural Insights Can Assist Governments in the Post-Pandemic World11.6.2021 10:15:00 CEST | Press release
The Secure Communities Forum, a global collaboration of security professionals, has convened a leading panel of experts to discuss how behavioural science can impact positive social cohesion, build on the concept of positive citizenship, and encourage positive individual behaviours. The virtual event was attended by 134 people from 18 countries. The Secure Communities Forum convened the webinar in response to the ongoing Covid-19 pandemic. Governments and law enforcement agencies have used behavioural science to encourage adherence to public health measures like social distancing and mask-wearing. Lindsay Juarez, Director at Irrational Labs, USA, opened the session, offering the view that we assume humans are rational, which is not the case. She said: “Behavioural science is about setting people up for success and breaking through the noise. Information isn't enough to change behaviour, the decision-making context matters. “People don’t always act in their own long-term best interests,
Luxembourg’s Supercomputer MeluXina is Operational11.6.2021 09:18:00 CEST | Press release
Luxembourg’s high performance computer MeluXina was officially launched on June 7 putting the country on the global map of computer super powers. MeluXina is capable of executing more than 10 Petaflops, the equivalent of 10 million billion calculations per second, which will rank it among the world’s top 50 supercomputers. The petascale computer is powered by green energy and is part-funded under the European High Performance Computing Joint Undertaking. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210611005115/en/ Minister of State Xavier Bettel; His Royal Highness Henri, Grand Duke of Luxembourg; Minister of the Economy Franz Fayot; EuroHPC Joint Undertaking Executive Director Anders Jensen (Photo: Business Wire) In a series of 8 high-performance computers in the EU, MeluXina joins Vega, another petascale supercomputer located in Slovenia, as the first EuroHPC machines to go live. Its innovative modular architecture allo
Vertex and CRISPR Therapeutics Present New Data in 22 Patients With Greater Than 3 Months Follow-Up Post-Treatment With Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at European Hematology Association Annual Meeting11.6.2021 09:05:00 CEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) and CRISPR Therapeutics (Nasdaq:CRSP) today announced new data on 22 patients,with follow-up of at least 3 months, and ranging from 4 months to 26 months, treated with the investigational CRISPR/Cas9-based gene-editing therapy, CTX001, that show a consistent and sustained response to treatment. CTX001 is being investigated in two ongoing Phase 1/2 clinical trials as a potential one-time therapy for patients suffering from transfusion-dependent beta thalassemia (TDT) and severe sickle cell disease (SCD). In total, more than 40 patients have been dosed across both studies to date. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210611005069/en/ All 15 patients with TDT, including six who have the beta zero/beta zero or other severe genotypes, were transfusion-free at last follow-up, and all seven patients with severe SCD were free of vaso-occlusive crises (VOCs) from CTX001 infu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom